Table 3 IC50 value for 5-FU after treatment with the PPARG agonists pioglitazone, rosiglitazone and the PPARG inhibitor GW9662
Treatment | IC50 (μM) average + standard deviation | p-value paired t-test | p-value Wilcoxon-Rank test | |
|---|---|---|---|---|
HT29 | Control | 31.4 ± 8.2 | ||
Pio 80 μM | 4.4 ± 0.8 | < 0.0001 | < 0.01 | |
Rosi 80 μM | 5.3 ± 0.7 | < 0.0001 | < 0.01 | |
GW9662 10 μM | 100.5 ± 69.9 | 0.03 | < 0.01 | |
SW403 | Control | 10.6 ± 1.9 | ||
Pio 80 μM | 3.8 ± 0.6 | < 0.0001 | < 0.01 | |
Rosi 80 μM | 5.0 ± 1.7 | < 0.001 | < 0.01 | |
GW9662 10 μM | 18.8 ± 16.1 | 0.19 | 0.426 |